ArticleJournal of the American Society of Nephrology : JASN2008
Chromogranin A polymorphisms are associated with hypertensive renal disease.
Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Tumour markers and kidney function: a systematic review.BioMed research international · 2014Pooled it
- The role of chromogranin A cleavage products in onset of type 1 and 2 diabetes.Frontiers in clinical diabetes and healthcare · 2026Review
- Inflammation Promotes Proteolytic Processing of the Prohormone Chromogranin A by Macrophages.Journal of the Endocrine Society · 2025Article
- Plasma catestatin levels are related to metabolic parameters in patients with essential hypertension and type 2 diabetes mellitus.Heart and vessels · 2024Article
- Role of Catestatin in the Cardiovascular System and Metabolic Disorders.Frontiers in cardiovascular medicine · 2022Review
- Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis.Biomolecules · 2021Article
- Chromogranin A pathway: from pathogenic molecule to renal disease.Journal of hypertension · 2020Article
- Relation of neuropeptide Y gene expression and genotyping with hypertension in chronic kidney disease.Biochemistry and biophysics reports · 2019Article
- Mice overexpressing chromogranin A display hypergranulogenic adrenal glands with attenuated ATP levels contributing to the hypertensive phenotype.Journal of hypertension · 2018Article
- Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.Journal of hypertension · 2016Article
- Molecular Mechanism for Hypertensive Renal Disease: Differential Regulation of Chromogranin A Expression at 3'-Untranslated Region Polymorphism C+87T by MicroRNA-107.Journal of the American Society of Nephrology : JASN · 2015Article
- MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension.Human molecular genetics · 2013Article
- Adrenergic genetic mechanisms in hypertension and hypertensive kidney disease.Electrolyte & blood pressure : E & BP · 2013Article
- The regulated secretory pathway and human disease: insights from gene variants and single nucleotide polymorphisms.Frontiers in endocrinology · 2013Article
- Target organ damage in African American hypertension: role of APOL1.Current hypertension reports · 2012Review
- Disorders of blood pressure regulation-role of catecholamine biosynthesis, release, and metabolism.Current hypertension reports · 2012Review
- Chromogranin peptides in brain diseases.Journal of neural transmission (Vienna, Austria : 1996) · 2011Review
- Gene polymorphism of vascular endothelial growth factor -1154 G>A is associated with hypertensive nephropathy in a Hispanic population.Molecular biology reports · 2011Article
- Catecholamine storage vesicles: role of core protein genetic polymorphisms in hypertension.Current hypertension reports · 2011Article
- Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease.Cellular and molecular neurobiology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
Abstract
Chromogranin A is released together with epinephrine and norepinephrine from catecholaminergic cells. Specific endopeptidases cleave chromogranin A into biologically active peptide fragments, including catestatin, which inhibits catecholamine release. Previous studies have suggested that a deficit in this sympathetic "braking" system might be an early event in the pathogenesis of human hypertension. Whether chromogranin A (CHGA) polymorphisms predict end-organ complications of hypertension, such as end-stage renal disease, is unknown. Among blacks, we studied common genetic variants spanning the CHGA locus in 2 independent case-control studies of hypertensive ESRD. Two haplotypes were significantly more frequent among subjects with hypertensive ESRD: 1) in the promoter (5') region, G-462A-->T-415C-->C-89A, haplotype ATC (adjusted odds ratio = 2.65; P = 0.037), and 2) at the 3'-end, C11825T (3'-UTR, C+87T)-->G12602C, haplotype TC (adjusted odds ratio = 2.73, P = 0.0196). Circulating levels of catestatin were lower among those with hypertensive ESRD than controls, an unexpected finding given that peptide levels are usually elevated in ESRD because of reduced renal elimination. We found that the 3'-UTR + 87T variant decreased reporter gene expression, providing a possible mechanistic explanation for diminished catestatin. In summary, common variants in chromogranin A associate with the risk of hypertensive ESRD in blacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.